Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Retained Earnings (2020 - 2026)

Immuneering's Retained Earnings history spans 7 years, with the latest figure at -$293.8 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 22.75% to -$293.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$293.8 million, a 22.75% decrease, with the full-year FY2025 number at -$280.3 million, changed N/A from a year prior.
  • Retained Earnings came in at -$293.8 million for Q1 2026, down from -$280.3 million in the prior quarter.
  • The five-year high for Retained Earnings was $5607.0 in Q3 2023, with the low at -$293.8 million in Q1 2026.
  • Historically, Retained Earnings has averaged -$108.4 million across 5 years, with a median of -$167395.0 in 2022.
  • Biggest five-year swings in Retained Earnings: surged 103.94% in 2023 and later crashed 22079357.38% in 2025.
  • Year by year, Retained Earnings stood at -$30120.0 in 2022, then soared by 97.42% to -$778.0 in 2023, then plummeted by 26503756.04% to -$206.2 million in 2024, then tumbled by 35.95% to -$280.3 million in 2025, then fell by 4.8% to -$293.8 million in 2026.
  • Business Quant data shows Retained Earnings for IMRX at -$293.8 million in Q1 2026, -$280.3 million in Q4 2025, and -$268.7 million in Q3 2025.